Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Atropine For Symptomatic Vitreous Floaters
NCT06174935Phase 2Not yet recruiting
- Start
- Jan 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of NVK002 in Eye floaters. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
NVK002
03
Conditions
Eye floaters
Beyond the preview
Go deeper on NCT06174935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06174935.